Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA.
J Nanobiotechnology. 2008 Oct 23;6:12. doi: 10.1186/1477-3155-6-12.
An approach to use multivalent dendrimer carriers for delivery of nucleoside signaling molecules to their cell surface G protein-coupled receptors (GPCRs) was recently introduced.
A known adenosine receptor (AR) agonist was conjugated to polyamidoamine (PAMAM) dendrimer carriers for delivery of the intact covalent conjugate to on the cell surface. Depending on the linking moiety, multivalent conjugates of the N6-chain elongated functionalized congener ADAC (N6-[4-[[[4-[[[(2-aminoethyl)amino]carbonyl]methyl]anilino]carbonyl]methyl]phenyl]-adenosine) achieved unanticipated high selectivity in binding to the cytoprotective human A3 AR, a class A GPCR. The key to this selectivity of > 100-fold in both radioreceptor binding (Ki app = 2.4 nM) and functional assays (EC50 = 1.6 nM in inhibition of adenylate cyclase) was maintaining a free amino group (secondary) in an amide-linked chain. Attachment of neutral amide-linked chains or thiourea-containing chains preserved the moderate affinity and efficacy at the A1 AR subtype, but there was no selectivity for the A3 AR. Since residual amino groups on dendrimers are associated with cytotoxicity, the unreacted terminal positions of this A3 AR-selective G2.5 dendrimer were present as carboxylate groups, which had the further benefit of increasing water-solubility. The A3 AR selective G2.5 dendrimer was also visualized binding the membrane of cells expressing the A3 receptor but did not bind cells that did not express the receptor.
This is the first example showing that it is feasible to modulate and even enhance the pharmacological profile of a ligand of a GPCR based on conjugation to a nanocarrier and the precise structure of the linking group, which was designed to interact with distal extracellular regions of the 7 transmembrane-spanning receptor. This ligand tool can now be used in pharmacological models of tissue rescue from ischemia and to probe the existence of A3 AR dimers.
最近引入了一种使用多价树状大分子载体将核苷信号分子递送到其细胞表面 G 蛋白偶联受体 (GPCR) 的方法。
将已知的腺苷受体 (AR) 激动剂与聚酰胺-胺 (PAMAM) 树状大分子载体缀合,以便将完整的共价缀合物递送到细胞表面。根据连接部分,N6-链延长的功能化同系物 ADAC(N6-[4-[[[4-[[[(2-氨基乙基)氨基]羰基]甲基]苯胺基]羰基]甲基]苯基]-腺苷)的多价缀合物出人意料地在结合细胞保护人 A3 AR 时表现出高选择性,A3 AR 是一种 A 类 GPCR。这种选择性 > 100 倍的关键是在放射受体结合(Ki app = 2.4 nM)和功能测定(抑制腺嘌呤环化酶的 EC50 = 1.6 nM)中保持游离氨基(二级)酰胺键连接的链。中性酰胺键连接的链或含硫脲的链的附着保持了对 A1 AR 亚型的中等亲和力和效力,但对 A3 AR 没有选择性。由于树突上残留的氨基与细胞毒性有关,因此这种 A3 AR 选择性 G2.5 树突的未反应末端位置以羧酸盐形式存在,这进一步增加了水溶性。A3 AR 选择性 G2.5 树突也被观察到与表达 A3 受体的细胞膜结合,但不与不表达受体的细胞结合。
这是第一个表明通过与纳米载体缀合以及设计用于与 7 次跨膜受体的远端细胞外区域相互作用的连接基团的精确结构来调节甚至增强 GPCR 配体的药理学特性是可行的示例。该配体工具现在可用于从缺血中挽救组织的药理学模型,并探测 A3 AR 二聚体的存在。